Evidence map›Paper›PMID 41986072›Full record

ArticleJournal for immunotherapy of cancer2026

Regional immunosuppression and associated systemic markers in focally relapsed sarcomatoid mesothelioma: case report.

Hely Ollila, Prateek Kulkarni, Hyojin Kim, Pratiti Ankola, Navin K Chintala, Carlos Thomas, Jennifer L Sauter, Michael Offin, Prasad S Adusumilli

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Single-Cell Pan-Cancer Atlas Reveals GPR171 as a Candidate Marker of CD8International journal of molecular sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hely OllilaThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Prateek KulkarniThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Hyojin KimThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Pratiti AnkolaThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Navin K ChintalaThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID http://orcid.org/0000-0003-4229-0977
Carlos ThomasThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jennifer L SauterDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Michael OffinDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Prasad S AdusumilliThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA adusumip@mskcc.org.ORCID http://orcid.org/0000-0002-1699-2046

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Tuning KITv CAR T cells for the solid tumor environmentR01CA292664 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Prasad S. Adusumilli · 2024 to 2026
$3.2M
CD28-KITv CAR T cells with PD-1 dominant negative receptorUG3CA290241 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ADUSUMILLI, PRASAD S. · 2024 to 2025
$3.1M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA292664NCI NIH HHS UG3 CA290241
6 · The paper itself

Abstract

A 52-year-old man presented with sarcomatoid diffuse pleural mesothelioma that had relapsed at an isolated site after a complete response to dual-immune checkpoint inhibition (ICI). Targeted sequencing exhibited amplification of chromosome 9p24, encompassing JAK2, PD-L1, PD-L2, and PTPRD in the relapsed (post-ICI) tumor, compared with baseline (pre-ICI). On multiplex immunofluorescence, tumor-associated macrophages (TAMs) and CD8

Indexed as

Biomarkers, TumorImmunosuppression TherapyMesotheliomaMesothelioma, MalignantNeoplasm Recurrence, LocalHumansMaleMiddle AgedT-Lymphocytes, CytotoxicBiomarkers, TumorGeneticImmune Checkpoint InhibitorMesothelioma

Identifiers

PMID41986072
PMCPMC13084882

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.